Janus kinase inhibitors: between prescription authorization and reimbursability.
Reumatismo
; 75(4)2023 Dec 19.
Article
em En
| MEDLINE
| ID: mdl-38115771
ABSTRACT
Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria set out in the prescription forms.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Reumatologia
/
Inibidores de Janus Quinases
Limite:
Humans
Idioma:
En
Revista:
Reumatismo
Ano de publicação:
2023
Tipo de documento:
Article